Concordia Biotech (CNTB, Financial) saw a significant increase in its stock price, rising by 5.48%. The stock is currently priced at $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%. The stock's amplitude is 4.61%.
According to the latest financial report, Concordia Biotech achieved a revenue of $24.12 million and a net profit of $7.65 million. The earnings per share stood at $0.14, with a gross profit of $23.64 million and a price-to-earnings ratio of -3.78.
One institution has rated the stock, with 100% recommending a buy and none suggesting hold or sell.
In the biotechnology sector, where the overall decline was 0.96%, certain related stocks showed strong performance. Tevogen Bio Holdings Inc (C/Wts 14/02/2029), Tc Biopharm (Holdings) Plc (C/Wts 10/02/2028), and Geovax Labs Inc (C/Wts 29/09/2025) experienced significant gains. Active stocks included Aditxt, Inc., Windtree Therapeutics, Inc., and Tc Biopharm (Holdings) Plc, with turnover rates of 1108.86%, 55.62%, and 51.27%, respectively. Highly volatile stocks in the related category were Pasithea Therapeutics Corp (C/Wts 12/08/2026), Apollomics Inc (C/Wts 01/04/2028), and Aditxt, Inc., with amplitudes of 145.55%, 60.44%, and 51.53%, respectively.
Concordia Biotech is a clinical-stage company focusing on developing next-generation immunomodulators for severe autoimmune diseases and inflammation. Its pipeline includes CBP-201, CBP-307, and CBP-174, leveraging expertise in T cell regulatory biology.
